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INTRODUCTION 
SOLID DISPERSION SYSTEM AND ITS HISTORICAL BACKGROUND 
One of the most useful methods to overcome the inherent difficulties 
associated with the formulation development of a sparingly water soluble drug is 
to enhance the solubility of the same. 
The enhancement of oral bio availability of poorly water soluble drugs 
remains one of the most challenging aspects of drug development. Although salt 
formation, solubilisation and particle size reduction have been commonly used to 
increase dissolution rate and there by oral absorption and bio availability of such 
drugs, there are practical limitations to these drugs.  They have been commonly 
used to increase dissolution rate and thereby oral absorption and bioavailability 
of such drugs. There are practical limitations to these techniques. The salt 
formation is not feasible for neutral drugs and synthesize of appropriate salt 
forms of the drugs that are weakly acidic or basic may not be practical. Even 
when salts are prepared, an increase in dissolution rate in gastro intestinal tract 
may not be achieved in many cases because of the reconversion of salts into 
their respective acid or base forms.  
Solid dispersions have been considered as means of increasing the 
solubility, dissolution and absorption of poorly soluble drugs.    This concept of 
solid dispersion was introduced by Sekiguchi and obi1. They suggested that the 
drug was present in a eutectic mixture in a micro crystalline state. 
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 Figure no : 1 Schematic Representation of the bio availability 
enhancement of poorly  water-soluble drug by solid dispersions compared 
with conventional tablet or capsule. 
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All the drug in solid dispersion might not be necessarily present in a 
microcrystalline state; a certain fraction of the drug might be molecularly 
dispersed in the matrix, thereby forming a solid solution. In either case, once the 
solid dispersion was exposed to aqueous media and carrier dissolved, the drug 
was released as very fine and colloidal particles. Because of greatly enhanced 
surface area obtained in this way, the dissolution rate and the bioavailability of 
poorly water soluble drugs were expected to be high. 
1.1 DIFFERENT TYPES OF SOLID DISPERIONS2 
a. Simple eutectic mixtures 
                Eutectic mixtures consist of two components which are completely 
miscible in the liquid state but only to a very limited extent in the solid state. Solid 
eutectic mixtures are usually prepared by rapid cooling of very fine crystals of the 
two components. When  the preparation is dissolved in aqueous medium the 
carrier will dissolve rapidly, releasing very fine crystals of the drug which offers 
large surface area that result in improvement of dissolution and there by 
improved bioavailability. 
b. Solid solutions 
              Solid solutions consist of just one phase in which drug and the carrier 
are in the solid state. The drug’particle size has been reduced to its absolute 
minimum and the dissolution rate is determined by the dissolution rate of the 
carrier. Thus by the judicious selection of a carrier, the dissolution rate of the 
drug can be increased up to several orders of magnitude. 
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Solid solutions can be classified according to two methods: 
According to their miscibility, continuous and discontinuous solid solution.              
According to the way in which the solvate molecules are distributed in the 
solvent, substitutional, interstitional and amorphous solution. 
• Continuous solid solutions 
In continuous solid solutions, the components are miscible in all 
proportions. The bonding strength between the two components is stronger than 
the bonding strength between molecules of each of the individual component. 
These types of solid dispersions are not used pharmaceutically. 
• Discontinuous solid solutions  
The solubility of each of the components is limited. The strategy of solid 
solutions for a dosage form depends upon the mutual solubility of the two 
components and also the dose of the drug component. 
• Substitutional crystalline solid solutions  
The substitutional crystalline solid solutions will have a crystalline 
structure, in which the solute molecules can either substitute for solvent 
molecules in the crystal lattice or fit into the interstices between the solvent 
molecules. 
• Interstitial crystalline solid solutions  
In interstitial crystalline solid solutions, the dissolved molecules occupy 
the interstitial spaces between the solvent molecules in crystal lattice. 
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• Amorphous solid solutions  
In amorphous solid solutions, the solute molecules are dispersed 
molecularly but irregularly with in the amorphous solvent. Using griseofulvin in 
citric acid. Chiou and Reigelmann3 were the first to report the formation of an 
amorphous solid solution to improve the dissolution properties. Other carriers 
used in early studied included urea and sugars such as sucrose, dextrose and 
galactose. More recently, organic polymers such as polyvinyl pyrrolidine (PVP), 
polyethylene glycol (PEG) and various cellulose derivatives are also used. 
• Glass solutions 
Glass solutions are a homogenous system in which the solute dissolves in 
a glassy solvent. A glass solution is a metastable form. The lattice energy is 
much less than a solid solution. So the dissolution of a drug in a glass solution 
should be theoretically faster than in solid solution. 
1.2 ADVANTAGES OF SOLID DISPERSIONS 
 Solid dispersions of drug in solid is helpful in stabilizing unstable drugs. 
Many of the advantages claimed for SD derived from their rapid dissolution rate. 
The increased rate of Nitrazepam from their Citric acid dispersion produce 
increase in the rate and extent of absorption. 
 Solid dispersions of drug in carrier offers solubility potential for sustained 
release polymeric materials e.g., copolymer C.A. II(R), a vinyl acetate copolymer 
with 11% Erotonic acid or Eudragit (R) have been co evaporated or fused to 
provide sustain release of Codeine. 
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 The PEGs may protect certain drugs e.g. cardiac glycosides against the 
decomposition by saliva and allow buccal absorption. 
Solid dispersions technology may also be used to solidify drugs e.g. 
Clofibrate and benzyl benzoate. 
 Finally the unique technique was claimed for Prednisolone-urea 
dispersion when incorporated in ointment base an increased diffusion of steroid 
from the ointment was obtained. 
1.3 LIMITATION OF SOLID DISPERSION SYSTEMS 
a. Its method of preparation 
b. Reproducibility of its physicochemical properties 
c. Its formulations into dosage forms 
d. The scale up of manufacturing processes and 
e. The physical and chemical stability of drug and vehicle 
f. Future aspects  
Despite of many advantages of solid dispersion issues related to 
preparation, reproducibility, scale up and stability limited its use in commercial 
dosage forms for poorly water soluble drugs. Successful development of solid 
dispersion systems for preclinical, clinical and commercial use have been 
feasible in recent years due to the availability of surface active and self-
emulsifying carriers with relatively low melting points. Because of the simplicity of 
manufacturing and scale up processes, the physicochemical properties and as a 
result the bio availability of solid dispersions are not expected to change 
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significantly during scale up. For this reason popularity of the solid dispersions to 
solve difficult bio-availability issues with respect to poorly water soluble drugs will 
grow rapidly. Because the dosage form can be developed and prepared using 
small amounts of drug substances in early stages of the drug development 
process, the system has an advantage, over the other commonly used bio-
availability enhancement techniques such as micronization of drugs and soft 
gelatin encapsulation. 
Research should also be directed towards identifications of vehicles or 
excipients that would retard or prevent the crystallisation of drug from super 
saturated systems. Attention must also be given to any physiological effects of 
carriers used. 
Physical and chemical stability of both drug and the carrier in a solid 
dispersion are major development issues, as exemplified by the recent 
withdrawal of Ritongx capsules from the market, so future research needs to be 
directed to address various stability issues. 
Although, as mentioned earlier, the direct filling of solid dispersion into 
hard gelatin capsules is a relatively simple process, there are very limited reports 
scale up of the technology. Further studies on scale up and validation of the 
process will be essential. 
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1.4 CARRIERS USED FOR SOLID DISPERSIONS4,5 
a. Poly ethylene glycols 
 Poly ethylene glycols are polymers of ethylene oxide  a molecular 
weight usually falling in the range of 200 - 300,000. For solid dispersions 
PEGs with a molecular weight of 1500 - 20,000 are usually used. As the 
molecular weight increases, so does the viscosity of PEG. Their solubility in 
water is generally good but decreases with molecular weight. A particular 
advantage of PEGs for the formation solid dispersions is that, they have good 
solubility in many organic solvents. 
b. Poly vinyl pyrrolidine  (PVP) 
  Polymerization of Vinyl pyrrolidine leads to Poly vinyl pyrrolidine (PVP) 
of molecular weight from 2500 - 3000,000. Due to their good solubility in a 
wide variety of organic solvents, they are particularly suitable for solvent 
method. Similarly to the PEGs, the PVPs have good water solubility and can 
improve the wettability of the dispersed compound in many cases. The 
aqueous solubility of PVPs becomes poorer with increasing chain length and 
further much higher viscosity at a given concentration. 
E.g. Poly vinyl alcohol, Poly vinyl pyrrolidine Acetate co-polymer. 
c. Urea 
 Urea has slightly diuretic effect and its solubility in water is greater than 
one and it also exhibits good solubility in water and many common organic 
solvents. In one of the first bioavailability studies of solid dispersion, it was 
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shown that sulphathiazole was better absorbed in rabbits when given as 
eutectic with urea. Similarly Goldberg et al  in 1966 reported faster dissolution 
rates of chloramphenicol when prepare with urea as carrier. 
1.5 CHARACTERIZATION OF SOLID DISPERSIONS4 
¾ The different methods that have been used to characterize solid 
dispersion are;    
¾ Thermo analytical methods, differential thermo analysis and hot stage 
microscopy. 
¾ Powder X-Ray diffraction. 
¾ Spectroscopic methods, especially IR spectroscopy. 
¾ Microscopic methods including polarization microscopy and  scanning 
electron microscopy. 
¾ Colorimetric analysis of the solution or melting enthalpy for calculation 
of entropy change. 
¾ Dissolution testing. 
a. Thermo analytical methods                    
 Thermo analytical methods include all that examine a characteristic of 
the systems as a function of temperature. Of this, Differential scanning 
colorimetry is the most highly regarded method. DSC enables the quantitative 
detection of all process in which energy is required or produced, i.e., 
endothermic and exothermic phase transition. The usual method of 
measurement is to heat the reference and two test samples in such a way 
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that the temperature of two is kept identical. 
 If an energy requirement transition occurs in the test samples, extra 
heat is applied to this sample so that its temperature climbs at the same rate 
as in the reference. The additional heat required is recorded and used to 
quantitate the energy or the phase transition. 
Exothermic transitions, such as conversion of one polymorph to a more 
stable polymorph, can be also detected. Lack of a melting peak in DSC of 
solid dispersion indicates that the drug is present in amorphous than the 
crystalline form. Since the method is quantitative in nature, the degree of 
crystallinity can also be calculated for systems in which the drug is partly 
amorphous and partly crystalline. However crystallinities of fewer than 2% 
cannot be generally detected with DSC. 
b. X-ray diffraction 
 The principle behind XRD is that when an x-ray beam is applied to 
sample, interference bands can be detected. The angle at which interference 
bands can be detected depends on the wavelength applied and the geometry 
of the sample with respect to periodicities in the structure. Crystalline sample 
is reflected by a characteristic finger point region in the diffraction pattern. 
Owing to the specificity of the finger print, crystallinity in the drug can be 
separately identified from crystallinity in the carrier. Therefore, it is possible 
with X-Ray Diffraction to differentiate between solid dispersions, in which it is 
partly present in crystalline form, regardless of whether the carrier is 
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amorphous or crystalline. However, crystallinities of under 5-10% cannot 
generally be detected with XRD. 
c. Infra red spectroscopy 
 Structural changes and lack of a crystal structure can lead to changes 
in bonding between functional groups which can be detected by Infra red 
spectroscopy. Since not all the peaks in the IR spectrum are sensitive to 
crystalline changes, it is possible to differentiate between those that are 
sensitive to changes in crystallinity and those that are not 
.d. Dissolution testing 
 Release rate cannot be used on a stand alone basis to determine 
whether a solid dispersion has been formed or not. However in conjunction 
with other physiochemical data, they provide strong evidence for the 
formation of a molecularly dispersed or nearly molecularly dispersed system. 
When the goal of preparing a solid dispersion is to improve dissolution 
characteristics of the drug, the results of the release rate experiments are 
obviously of prime importance in assessing the success of the approach. Well 
designed release experiments will show whether the solubility of the drug and 
its dissolution rate can be enhanced, and also whether the resulting 
supersaturated solution is stable or tends to precipitate quickly. Comparison 
of results with those for pure drug powder and physical mixture can help to 
indicate the dissolution via solubilization and wetting which could be affected. 
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1.6 SOLID DISPERSION TECHNIQUES5,6 
a. FUSION METHOD OR MELTING TECHNIQUE  
This fusion or wafting method was proposed by Sekiguchi and Obi to 
prepare fast release solid dispersion dosage forms. This is technically the 
easiest method of preparation provided the drug and the carrier are miscible 
in the molten state. The melted mixture is collected and solidified in  an ice 
bath under vigorous stirring. The final mass is crushed, pulverized and 
sieved. This technique subsequently employed with modification of Goldberg 
et al to facilitate fast solidification. The homogenous melt was poured in form 
of a thin layer onto a ferric plate or a stainless steel plate and cooled by 
flowing air or water onto the opposite side of the plate. The solidified masses 
were stored in the dessicator at ambient temperature for hardening and ease 
of powdering.   
Advantage 
1. Simplicity and economy of process are the main advantages of this 
method. 
2. Super saturation of a solute or a drug in a system can be often 
obtained by quenching of the melt rapidly from high temperature. 
Disadvantage 
1. Many substances, either drug or carrier may decompose or evaporate 
during the fusion process at high temperature. 
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Examples of solid dispersion prepared by this  method 
Solid dispersion of Acetaminophen, Griseofulvin, Primidone, 
Chloropropamide,Chloramphenicol,Tolazamide,Steroids,Ketoprofen, 
Nimuselide. 
b. Solvent evaporation method(SEM) 
 This method involves (Tantishaiyakul et al., 1999) dissolving a physical 
mixture of two solid components in a common solvent, followed  by 
evaporation of the solvent. The mass was then stored in dessicator, 
pulverised and sieved. Solid dispersion prepared by this technique was 
termed by bates et al., as Co-Precipitate. They should be more correctly be 
designated as “Co-evaporates”. 
Advantage 
1. The thermal decomposition of drugs or carriers can be prevented 
because of the low temperature required for evaporation of organic 
solvents. 
Disadvantages 
1. Higher cost of preparation 
2. Difficulty in completely removing the solvent 
3. Possible adverse effect of the negligible amount of solvent on the 
chemical stability of the drug. 
Examples of solid dispersion prepared by this method  
Griseofulvin-PVP, Sulfathiazole-PVP. 
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c. Melting solvent method  
This is not a common method and is not specified in most books and 
journals .In this method the drug is dissolved in a suitable liquid solvent and 
the solution is then incorporated directly into the melt of carrier obtained 
below 70o C with out  the removal of the liquid solvent. 
Advantages 
1. Posses the advantages of both melting and solvent methods. 
  Disadvantages 
1. This method is suitable only for drug whose therapeutic dose is below 
50 mg. 
2. Selected solvent or dissolved solution  may be not miscible with the 
melt of the carrier. 
Examples of solid dispersion prepared by this method 
Solid dispersion of Clofibrate, Methyl salicylate, Benzyl benzoate, 
Spiranolactone,  Di-α-Tocopherol acetate etc. 
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Table no : 1 SOLID DISPERSIONS OF THERAPEUTIC AGENTS 
 
Drug Carrier Method 
Type of 
solid 
Dispersion 
Effect of 
Dissolution 
Rate 
Triamterene 
Β-
cyclodextrin 
S, K Not Studied Increased 
Flurbiprofen PVP S Not Studied Increased 
Caffeine Nicotinamide M Peritech Increased 
Chloramphenicol Urea M 
Solid 
Solution 
Increased 
Clofibrate PEG 6000 M, S Not Studied Increased 
Corticosteroids Sugars M Not Studied Increased 
Diazepam PEG 4000 M 
Eutectic with 
solid 
Solution 
Not Studied 
Griseofulvin Succinic acid M 
Solid 
Solution 
Increased 
 PVP S Not Studied Increased 
 PVP-30 
Spray 
Embedding 
Solid 
Solution 
Increased 
 PEG -4000 M, S Not Studied Increased 
 PEG -6000 M, S Not Studied Increased 
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 PEG-2000 M, S Not Studied Increased 
 
Anhydrous 
citric acid 
M 
Glass 
suspension 
Increased 
Indomethacin PEG 6000 M Not Studied Increased 
Methyl salicylate PEG 6000 M,S Not Studied Increased 
Paracetamol Urea M 
Solid 
solution 
Increased 
Mannitol M Eutectic Increased  
Primidone Citric acid M 
Glass 
solution 
Increased 
Reserpine PVP S Not Studied Increased 
 Cholanic acid S Not Studied Increased 
 
Deoxychoilic 
acid 
S Not Studied Increased 
Sulfathiazole Urea M 
Simple 
eutectic 
Not Studied 
Tolubutamide PEG-4000 S Not Studied Increased 
 PEG-6000 S Not Studied Increased 
 
PEG 
4000+6000 
M, S Not Studied Increased 
 PEG-2000 M, S Monoacetic Not Studied 
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 PVP S Not Studied Increased 
 
Polyoxyl 40 
stearate 
M, S Not Studied Increased 
 PEG-8000 M, S Not Studied Increased 
 PVP S Not Studied Increased 
 PEG-6000 S Not Studied Increased 
 PEG-4000 M Not Studied Increased 
Allopurinol PVP S Not Studied Increased 
Benzybenzoate PEG 6000 M, S Not Studied Increased 
 
1.7   NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)7,8,9 
The anti inflammatory, analgesic and antipyretic drugs are the 
heterogeneous group of compounds often chemically unrelated and share 
certain therapeutic action and side effects. They act primarily on the peripheral 
pain mechanisms but also on CNS to release pain threshold.  
   An ideal anti-inflammatory drug should effect only aberrant, uncontrolled 
inflammation by modifying response to disease but not to interfere with normal 
inflammation process, which is a part of the body’s vital defence mechanism to 
its major environment insults or invading micro-organisms. 
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NSAIDS may be classified as 
A. Non selective cox inhibitors (conventional NSAIDS) 
1. Salicylates 
  Aspirin, Diflunisal 
2. Pyrazolone derivatives 
  Phenylbutazone, Oxyphenylbutazone 
3. Indole derivatives 
  Indomethacin, Sulindac 
4. Propionic acid derivatives 
  Ibuprofen, Naproxen, Ketoprofen, Flubiprofen. 
5. Arthraniic acid derivatives 
  Mephenamic acid 
6. Aryl-acetic acid derivatives 
  Diclofenac 
7. Oxicam derivatives 
  Piroxicam, tenoxicam 
8. Pyrrolo-pyrrole derivatives 
  Ketorolac 
9. Preferential cox-2 inhibitors 
  Nimesulide, Meloxicam, Nebumentone 
10. Selective Cox-2 inhibitors: 
      Celecoxib, Rofecoxib, Valdecoxib  
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B. Analgesic-antipyretics with poor anti-inflammatory action 
1. Para amino phenol derivatives: paracetamol 
2. Pyrazolone derivatives: Metamizol (Dipyrone) Propiphenazone 
3. Benzoxazocine derivative: Nefopam. 
Mechanism of Action of NSAIDs 
     NSAIDs are generally inhibitors of the enzymes, cyclo-oxgenase which 
results in the direct inhibition of the bio-synthesis of prostaglandins and 
thromboxanes from arachidonis acid. There are two forms of cyclo-oxygenase, 
COX-1, which is constructive form of the enzyme and COX-2, whuch is the form 
induced in the presence of inflammation. Inhibition of COX-2, is therefore thought 
to be responsible for at least some of the analgesic, anti-inflammatory and anti-
pyretic properties of NSAIDs, where as inhibition of COX-1 is thought to produce 
some of their side effects, mainly on gastro-intestinal tract. Most NSAIDs is in 
clinical use inhibit COX-1 and COX-2. 
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DRUG PROFILE 
 
INDOMETHACIN 10,11,12,13 
                           
Chemistry  
          1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H- Indole-3-acetic acid 
Category  
    Anti-inflammatory, Analgesic   
Description  
       White to pale yellow, crystalline powder, odourless  
Molecular weight  
             357.79 
Empirical formula 
             C19H16NO4Cl 
Solubility  
           Soluble in chloroform; sparingly soluble in ethanol (95%) and practically 
insoluble in water  
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Storage  
        Stored in well closed, light resistant containers  
Pharmacodynamics 
Mechanism of action  
Indomethacin has prominent antiinflammatory and analgesic-antipyretic 
properties similar to those of the salicylates. Indomethacin is a more potent 
inhibitor of the cyclooxygenases than is aspirin, but patient intolerance generally 
limits its use to short-term dosing. Indomethacin has analgesic properties distinct 
from its antiinflammatory effects, and there is evidence for central and peripheral 
actions. 
Pharmacokinetics and metabolism  
Oral Indomethacin has excellent bioavailability. Peak concentrations occur 
1 to 2 hours after dosing. Indomethacin is 90% bound to plasma proteins and 
tissues. The concentration of the drug in the CSF is low, but its concentration in 
synovial fluid is equal to that in plasma within 5 hours of administration. Between 
10% and 20% of indomethacin is excreted unchanged in the urine, partly by 
tubular secretion. The majority is converted to inactive metabolites. 
Half life 
        The half-life in plasma is variable, perhaps because of enterohepatic 
cycling, but averages about 2.5 hours. 
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Therapeutic uses 
Indomethacin is effective for relieving joint pain, swelling, and tenderness, 
increasing grip strength, and decreasing the duration of morning stiffness.   
•  It is estimated to be approximately 20 times more potent than 
aspirin. 
• It suppresses inflammation in a manner similar to steroids, but 
less side effects of sedation.  
• They are widely used for the treatment of inflammatory disorders 
and painful conditions such as rheumatoid arthritis, gout, bursitis, 
painful menstruation, and headache 
Drug Interactions 
          Indomethacin does not directly modify the effect of warfarin, but 
platelet inhibition and gastric irritation increase the risk of bleeding, concurrent 
administration is not recommended. Indomethacin antagonizes the natriuretic 
and antihypertensive effects of furosemide and thiazide diuretics and blunts 
the antihypertensive effect of β-receptor antagonists, AT1 receptor 
antagonists, and ACE inhibitors. 
Adverse Effects  
        A very high percentage (35% to 50%) of patients receiving usual 
therapeutic doses of indomethacin experience untoward symptoms, and 
about 20% must discontinue its use because of the side effects. Most adverse 
effects are dose-related. 
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     Gastrointestinal complaints are common and can be serious. 
Diarrhoea may occur and sometimes is associated with ulcerative lesions of 
the bowel. Underlying peptic ulcer disease is a contraindication to 
indomethacin use. Acute pancreatitis has been reported, as have rare, but 
potentially fatal, cases of hepatitis. 
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POLYMER PROFILE 
CARRIERS USED IN THIS PROJECT 
SELECTION OF A SUITABLE CARRIER14 
A carrier chosen for the solid dispersions is designed to increase the 
dissolution rate of drugs should meet the following requirements 
I. Freely soluble in water with intrinsic rapid dissolution properties. 
II. Should be non toxic. 
III. Pharmacologically inert. 
IV. Chemically compatible with drug. 
V. Carrier  should be soluble in a variety of organic solvents. 
VI. Melting point not much higher than the drug. 
The  carriers used in the study are β-cyclodextrin and hydroxyl propyl 
β-cyclodextrin. 
β-CYCLODEXTRIN15,16,17 
Synonyms: beta-cycloamylose, beta-dextrin, Cycloheptaamylose, Kleptose,    
Cavamax W7 pharma, Cyclomalto- Heptose                                                           
Appearance :   white crystalline powder              
Empirical formula :   C42H70O35 
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Molecular structure 
                    
Molecular weight : 1135 
Melting point :  255-265oC 
Solubility: 1 in 200 parts of PEG at room temperature 1 in 50 parts of water 
at 200C Insoluble in acetone , ethanol  (95%) and methylene Chloride 
Compressibility :  21.0-44.0% 
Density(Bulk) :  0.523 g/cm3 
Density(Tapped) :  0.754 g/cm 
Particle size distribution :  7.0-45.0 µm 
Specific rotation at (250C) :  +162.0 
Surface tension:  71 m N/m (71 dynes/cm) 
Chemical name and CAS  Registry Number :  β-cyclodextrin [7585-39-9] 
Empirical formula    :   C42H70O35 
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Functional category  : Solubilizing agent, stabilizing  agent                            
STABILITY  AND STORAGE CONDITION 
β-cyclodextrin and other cyclodextrins are stable in a solid state if  
protected from high humidity. Cyclodextrins should be stored in a tightly 
closed container, in a cool and dry place. 
INCOMPATIBILITIES 
The activity of some anti microbial preservatives in aqueous solution  
can be reduced in presence of cyclodextrins. 
APPLICATION IN PHARMACEUTICAL TECHNOLOGY 
Cyclodextrins are bucket like or cone like toroid molecules, rigid 
structure and a central activity, the size of which varied according to the 
cyclodextrin type. The internal surface of the cavity is hydrophobic and the 
outside of the torus is hydrophilic, due to the arrangement of the hydroxyl 
groups with in a molecule. This arrangement permits the cyclodextrin to 
accommodate a guest molecule with in a cavity,forming  an inclusion 
complex. Cyclodextrin may be used to form inclusion complexes with a 
variety of drug molecules, resulting primarily in improvements of dissolution 
and bioavailability owing to enhanced solubility and improved chemical and 
physical stability. 
I. β-cyclodextrin is considered to be non toxic when  
i. administered orally and is primarily used in tablet and 
capsule formulations 
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2. β-cyclodextrin may be used in both wet granulation and direct 
compression. 
3. β-cyclodextrin can be used in Eye drops solutions, Suppositaries, 
cosmetics. 
CYCLODEXTRINS IN MONOMOLECULAR INCLUSION COMPLEXATION 
Monomolecular inclusion complexes involve the entrapment of a single 
in the cavity of one host molecule. Monomolecular host structures are 
represented by cyclodextrins. 
Their ability to form inclusion compounds in aqueous solution is due to 
the typical arrangement of the glucose units.The molecule actually exists as a  
 
 
truncated cone. The interior of the cavity is relatively hydrophobic because of 
the CH2 groups, where as the cavity entrances are hydrophobic owing to the 
presence of the primary and secondary hydroxyl groups. β-cyclodextrins are 
having internal diameter almost 6A0.Cyclodextrins are studied as solubilising 
and stabilizing agents in pharmaceutical dosage form. 
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Description: 
β-cyclodextrins occur as white, practically odourless, fine crystalline 
powders, having a slightly sweet taste. Some cyclodextrin derivatives occur  
as amorphous powders. 
Typical properties of β-cyclodextrins 
Compressibility                       :            21- 44% 
Density (bulk)                         :            0.523g/cm3 
Density (tapped)                      :            0.754g/cm3 
Melting point                           :             255-2650C 
Moisture content                      :            13.0 – 15.0% w/w 
Particle size distribution           :            7.0 – 45.0 µm 
Physical characteristics: 
Solubility: 
         Soluble 1 in 200 parts of propylene glycol, 1 in 50 of water at 200C, 1 in 
20 at 500C, practically insoluble in acetone, ethanol (95%) and methylene 
chloride. 
Specific rotation                     :        +162.0 
Surface tension ( at 250C)      :         71 mN/m (71 dynes/cm) 
Stability and Storage Conditions 
           β-cyclodextrin and cyclodextrins are stable in the solid state if 
protected from humidity. Cyclodextrins should be stored in a tightly sealed 
container, in a cool, dry place.   
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Method of manufacture 
 Cyclodextrins are manufactured by the enzymatic degradation of 
starch using specialized bacteria. For example, β-cyclodextrin is produced by 
the action of the enzyme cyclodextrin glucosyl transferase upon starch or 
a starch hydrosylate. An organic solvent was used to direct the reaction that 
produces β-cyclodextrins and to prevent the growth of micro-organisms 
during the enzymatic reaction. 
Incompatibilities: 
 The activity of some antimicrobial preservatives in aqueous solution 
can be reduced in the presence of Hydroxypropyl-β-cyclodextrins. 
2-HYDROXYPROPYL β-CYCLODEXTRIN 
CAS number    :    (98513-20-3) 
Appearance :    white crystalline powder 
Molecular structure:  
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Synonyms  :   2HPβ-CD 
Solubility  :   white crystalline powder 
Surface tension :   52-69 mN/m (52-69ynes/cm at 250C)                                                   
Applications are similar to those for β-cyclodextrin. However it is not 
nephrotoxic and has been suggested to use in parenteral formulations. The 
oral and parenteral formulations of HPβ-CD are licensed in Europe and USA. 
The degree of substitution of hydroxypropyl groups may vary. 
Safety of cyclodextrins 
Cyclodextrins administered orally is metabolised by microflora in colon, 
forming the metabolites maltose, maltodextrin and glucose, which are 
themselves further metabolized before being finally excreted as CO2 and H2. 
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REVIEW OF LITERATURE 
 
 Chowdary KPR and Hynavathi R et.al.,18 studied the 
enhancement of dissolution rate of meloxicam. Solid dispersions of 
meloxicam in polyvinyl pyrrolidine, hydoxy propyl methyl cellulose, 
hydroxyl propyl cellulose, polyethylene glycol 6000 and solvent deposited 
systems on lactose, soluble starch, methyl crystalline cellulose, di calcium 
phosphate, silica gel and their selected tablet formulations were 
investigated with an objective of enhancing the dissolution rate of 
meloxicam. A marked enhancement in the dissolution rate and dissolution 
rate of meloxicam. A marked enhancement in the dissolution rate and 
dissolution efficiency of meloxicam was observed with all solid dispersions 
and solvent deposited systems. Among the carriers used, PVP gave 
highest enhancement in the dissolution rate of meloxicam at 1:9 ratio of 
drug and carrier and in case of solvent deposited systems MCC and DCP 
gave the maximum enhancement of dissolution rate. 
  Duncan Q.M. Craig et.al.,19 reported the mechanism of drug 
release from solid dispersions in water soluble polymers. In this review the 
concusses with regard to the solid structure and dissolution properties of 
solid dispersion is critically assessed. In particular the theory of carrier and 
drug controlled dissolution were highlighted. A model is proposed where 
by the release behaviour from the dispersions may be understood in terms 
of the dissolution or otherwise of the drug into the concentrated aqueous 
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polymer layer adjacent to the solid surface, including a derivation of an 
expansion to describe the release of intact particles from the dispersions. 
Nagaraja.P et.al.,20 sensitive spectrophotometric method for the 
determination of indomethacin in capsules. A single, sensitive and 
selective spectrophotometric method for the determination of 
indomethacin (INM) either in pure form or in capsules is described. The 
method is based on the coupling reaction of hydrolysed INM with 
diazotized p-phenylenediamine dihydrochloride (PPDD)  in sulphuric acid 
medium o give to give a red coloured product having the absorption 
maximum at 510 nm. The product is stable for20 hours. 
Beer’s law is obeyed in the concentration rng of 0.2-10µg/ml. 
Results of the proposed method compare favourably with those of the 
official methods and offer the merits of sensitivity and stability. Common 
excipients used as additives in pharmaceutical preparations do not 
interfere in the proposed method. 
Tirkkonen.S et.al.,21 buffer controlled release of indomethacin from 
ethylcellulose microcapsules. The rate of release of indomethacin from 
ethyl cellulose microcapsules prepared from co-acervation was studied 
using internal buffer, dibasic sodium phosphate (DSP), to increase the 
solubility of the core. The dissolution rate of the drug was determined in 
phosphate buffer solutions of varying pH and concentration. The role of 
the stagnant diffusion layer at the microcapsule surface was also 
evaluated by changing the mixing in the dissolution test. Indomethacin 
release was accelerated considerably with increasing amounts of DSP in 
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the core. DSP increases the pH inside the microcapsules, thus enhancing 
the release of the acidic drug. Increasing bulk solution pH increased the 
release rate of indomethacin, the enhancing effect being more 
pronounced with buffered microcapsules. Neither increasing phosphate 
concentration of the bulk solution nor increasing mixing of the 
microcapsules influenced the rate of release of indomethacin from 
unbuffered capsules. With buffered capsules the increase in phosphate 
concentration of bulk solution prevented leaching out of internal phosphate 
increasing in the release rate of indomethacin. The release of 
indomethacin also accelerated slightly with increasing mixing. 
Casella.R et al22., solid state β-cyclodextrin complexes containing 
indomethacin, ammonia and water. In formation studies. Five samples 
were prepared with β-cyclodextrin and the insoluble , non-steroidal, anti-
inflammatory drug indomethacin. The complexes were found to contain 
the drug , water and ammonia in several unique combinations. It was 
theorized the complex were tri-molecular in nature and their formation was 
controlled by a hydrophobic/hydrophilic balance created within the β-
cyclodextrin ring cavity prior to complex formation. Each complex was 
characterized by ultra-violet, infrared, NMR, powder X-ray diffraction, DSC 
and thermogravimetric techniques. These characterizations revealed 
distinct differences among the five complexes. 
Sanjula Baboota et.al.,23 have studied the formulation of tablet 
containing inclusion complexes of meloxicam, a non steroidal anti-
inflammatory drug ( NSAIDs), with betacyclodextrin  and 2-hydroxy propyl 
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betacyclodextrin. Inclusion complexes were prepared by freeze drying 
method and formed inclusion complexes were evaluated by FT-IR, X-ray 
diffraction, DSC and scanning electron microscopy. The dissolution 
studies revealed that all the formulation showed an increased rate and 
was more in alkaline medium, which may be due to the ionisation of the 
drug as it is a weak acid. The  DSC thermograms of meloxicam  displayed 
its endothermic melting peak at 2520c indicating the formation of string 
cyclodextrin-drug complex. The FT-IR spectra indicates possibility of 
interaction between β-CD/HP-βCD and conversion of meloxicam to 
amorphous state during freeze drying. 
Chowdary K.P.R et.al.,24 has studied the dissolution enhancement 
of itraconazole by  complexation with β- and hydroxypropylβ-cyclodextrin 
(HPβ-CD). The formation of itraconazole (ITR) with β-cyclodextrin (β-CD) 
and hydroxypropyl β-cyclodextrin (HPβ-CD) in aqueous solution and in 
solid state and the possibility of improving the solubility and dissolution 
rate of ITR via complexation with the above cyclodextrins were 
investigated. The phase solubility studies indicated the formation of a 1:1 
inclusion complex in solution with both β-CD and HPβ-CD. the apparent 
stability constant (kc) was 206.2M-1 AND 270M-1 for β-CD and HPβ-CD 
complexes, respectively. DSC studies indicated the formation of solid 
inclusion complexes of ITR – β-CD and ITR – HPβ-CD at 1:4 ratio only. 
Solid complexes of ITR – β-CD and ITR – HPβ-CD (1:1and 1:2 M) 
prepared by kneading and co-evaporation methods exhibited higher rates 
of dissolution and dissolution efficiency values than the corresponding 
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physical mixtures and ITR itself. Higher dissolution rates were observed 
with kneaded complexes than those prepared by complexation 
techniques. Increases of 23.4 fold and 83.4 fold in the dissolution rate 
were observed respectively with ITR – β-CD (1:2M) and ITR – HPβ-CD 
(1;2 M) kneaded complexes. 
 Sardar Ameer Ali et.al.,25 has studied the effect of β-CD on 
piroxicam pharmacokinetics and on in-vitro absorption using in situ rat gut 
technique. Complexation of the drug in the gastrointestinal fluid may alter 
the rate and extent of absorption of the drug. Since the complex formation 
very well applied in the administration of water soluble complexes of drug; 
that are incompletely absorbed because of poorly water solubility; the 
effect of β-CD on piroxicam pharmacokinetics and on in vitro absorption 
was studied. The pharmacokinetics of piroxicam, a potent anti-
inflammatory agent and piroxicam in combination with β-CD was studied 
in 9 healthy human volunteers. The plasma concentration of piroxicam 
was assayed by UV spectrophotometric method. The relative 
bioavailability of piroxicam is only 11% on comparing with the formulation 
containing piroxicam and β-CD in combination. In vitro absorption study 
using in situ rat gut technique showed a great rate of transport of 
piroxicam when combined with β-CD. This increase in bioavailability and 
rate of transport is due to the formation of inclusion complex by β-CD 
which in turn increases the solubility. 
Nalluri Buchi, Chowdary K.P.R et.al.,26  has studied inclusion 
complexation and dissolution properties of nimesulide and meloxicam  
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hydroxypropyl-β-yclodextrin binary systems. The purpose of the work is 
physicochemical characterisation of nimesulide (NI) meloxicam(ME) – 
hydroxypropyl-β-cycloextrin (HP-β-CD) binary systems both in solution 
and solid states and to improve the pharmaceutical properties of NI and 
ME via inclusion complexation with HP-β-CD. Binary systems of NI and 
ME with HP-β-CD have been characterised both in solution and solid state 
by different physicochemical methods. Three types of drug – HP-β-CD 
binary systems namely physical mixtures (PM), kneaded system (KS) and 
co-evaporated system (CS) in 1:1 and 1:2 molar ratios were prepared. 
Phase solubility and H-NMR spectroscopic studies in solution state 
revealed 1:1 complexation of NI and ME with HPβ-CD. A partial inclusion 
of NI with HPβ-CD at both molar ratios of kneaded an co-evaporated 
systems and a true inclusion of ME with HPβ-CD at both molar ratios of 
co-evaporated systems in solid state was confirmed by differential 
scanning calorimetry (DSC), powder X-ray diffractometry ( powderX-RD) 
an d scanning electron microscopy ( SEM) studies. Dissolution properties 
of NI and ME-HPβ-CD binary systems were superior when compared to 
corresponding pure drugs. The aqueous solubility and dissolution 
properties of NI and ME can be improved by inclusion complexation with 
HPβ-CD. 
Roger A. Rajewski et.al.,27 studied pharmaceutical applications of 
cyclodextrins-2. In-vitro drug delivery. The objective of this review is to 
summarise and obtain recent findings and applications of both modified 
and unmodified cyclodextrins for in vivo drug delivery. This review focuses 
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on the use of cyclodextrins for parenteral, oral, ophthalmic and nasal drug 
delivery. Other routes including dermal, rectal and pulmonary delivery are 
also briefly addressed. This  primarily focuses on the newer findings 
concerning cyclodextrin derivative which are likely to receive regulatory 
acceptance due o improved  aqueous solubility and safety profiles as 
compared to this modified cyclodextrin. Many of the applications reviewed 
involve the use of hydroxyl propyl β-cyclodextrin (HPβ-CD) and sulfo butyl 
ether β-cyclodextrin (SBC β-CD), which show promise of reactor safety 
while maintaining the ability to form inclusion complexes. The advantages 
and limitations of HPβ-CD and SBC β-CD and another cyclodextrins are 
addressed. 
 Juzio Nishijo et.al.,28 studied inclusion complex of 8-anilino 
naphthalene-1-sulfonate with β-CD. The interaction of 8-
anilinonaphthalene-1 sulfonate with β-CD was investigated in 0.1M 
phosphate buffer at pH7.4 by fluorescence spectrophotometry. Utilizing 
the fact that the fluorescence intensity of 8-anilinonaphthalene-1-sulfonate 
increases in the presence of β-cyclodextrin, the thermodynamic 
parameters for the inclusion complex formation were determined as 
follows: ∆0G = -2.52 Kcal /mol at 250C, ∆H0 = 1.92 Kcal/mol, and ∆S0 = 
2.1 eu. The driving forces for the inclusion complex formation were 
considered to be vanderwaals-london dispersion force and hydrophobic 
interaction. Also, for the measurements of 1H-NMR spectra and from 
studying the corey- pauling-koltun (CPK) model, the structure of the 
inclusion complex was discussed. 
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 Alison R. Green et.al.,29 studies heptakis (2,6-di-o-methyl) β-
cyclodextrin complexation with antitumor agent chlorambucil. The effects 
of heptakis (2,6-di-o-methyl)- [3-cyclodextrin (DIMEB) and of β-CD on the 
aqueous solubility and stability of chlorambucil (CHL) have been 
compared. In the presence o 1.3 Х 10-3 M DIMEB, there is a greater than 
20-fold increase in the stability of chlorambucil at 370C, ph 4.13. Aqueous 
solubility of CHL IS increased more than 40-fold in the presence of 1.74 Х 
10-2M DIMEB. The solubility was under the conditions where degradation 
is minimised (3.00C, ph 4.13). In the presence of 1.3 Х 10-3 M β-CDs, there 
is a four fold increase in the stability, and with1.74 Х 10-2M β-CD, there is 
a three fold increase in the aqueous solubility of CHL under similar 
conditions. Stability constants of CHL complex with DIMEB were 
determined kinetically and spectrophotometrically under various 
experimental conditions assuming 1:1 inclusion complex formation. 
Deasy.P.B  et.al.,30 use of extrusion-spheronization to develop an 
improved oral dosage dorm indomethacin. Two new pelletized 
formulations of indomethacin were developed and compared against 
pellets from the proprietary product, Indocid-R. Exclusive dissolution 
testing involving pH-shift and tophographical profiting showed that the new 
product containing PVP had slightly faster in vitro release than the 
commercial product, but surprisingly the other new product containing SLS 
had reduced drug release. The cause of the anomalous result was shown 
by solubility studies and  scanning electron microscopy to be related to the 
ability of the wetting agent to promote fragmentation of the microcrystalline 
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cellulose used as spheronization aid  into small crystallites, retarding drug 
release. The two new products had improved specificity compared to the 
proprietary product when examined by image analysis. However, on in 
vivo testing in dogs, the new product contaning sodium lauryl sulphate had 
the highest bioavaibility of the three preparations examined due to its 
effect as a penetration enhancer. 
Daisuke Iohara et.al.,31   preparation of amorphous indomethacin 
from aqueous 2,6-di-0-methyl-β-cyclodextrin solution. Indomethacin 
precipitated exclusively in an amorphous form from aqueous 2,6-di-o-
methyl-β-cyclodextrin solutions, whereas it precipitated in form of               
V polymorph from the solutions of the drug alone, parent cyclodextrins and 
2-hydroxypropyl-cyclodextrins. The polymorphic transition of the 
amorphous form to form V crystals in aqueous solution was markedly 
inhibited by he addition of 2,6-di-0-methyl-β-cyclodextrin, keeping the 
amorphous state for at least 5 days at 40C, where as it quickly transformed 
to form V crystals in the absence of 2,6-di-o-methyl-β-cyclodextrin, and it 
suppressed the solution mediated polymorphic transition of amorphous 
form of indomethacin to form V crystals in aqueous solution. The current 
results suggested that 2,6-di-o-methyl-β-cyclodextrin is useful for isolation 
of amorphous indomethacin. 
Karneto Uekama et.al.,32 (1992) studied the inhibitory effect of 2-
Hydroxy Propyl β-cyclodextrins on crystal growth of Nifedipine during 
storage. To prevent the crystal growth of Nifedipine during storage 2-
Hydroxy Propyl β-cyclodextrin was employed as a hydrophilic drug carrier 
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and compared polyvinyl Pyrrolidine. Although PVP initially retarded the 
crystallization of Nifedipine it failed to control the increase of crystal size 
after prolonged storage. 
Suresh and Pradesh33., (1999) were studied about the solid 
dispersion of curcumin. They used the different carrier such as HPMC, 
HEC, PVP, high molecular weight PEG such as 1500, 4000, 20000, 
polyaxomars such as cremophor and lutrol-127 for the preparation of solid 
dispersions. Both fusion and solvent methods were adopted curcumin was 
successfully solubilised using cremophor and PEG 20000 Release pattern 
may be first order kinetics. 
Nageswara Rao et.al.,34 (2001) studied on maltodextrin-piroxicam 
solid dispersions. They concluded that the solubility of the piroxicam 
increased linearly with increase in maltodextrin concentration. From SC 
results no compatibility problem recognized. An improvement in the 
dissolution rate of piroxicam in solid dispersions with maltodextrin was 
demonstrated. 
The improvement in the dissolution efficiency of poorly soluble 
naproxen was demonstrated by Patil et al.,(2001) they prepared the solid 
dispersions by common solvent method and melting method by using the 
carriers  PEG6000 , PEG4000  and polyvinyl pyrrolidine. From the dissolution 
studies the pure only 56.5% was dissolved, but the dissolution of the drug 
was increased with increase in carrier’s ratio in the formulations. They 
concluded that among the two methods, the melting method was 
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satisfactory and showed dissolution of drug PEG6000   is a suitable carrier 
for Naproxen to enhance the dissolution rate. 
Masataka saito et.al.,35 (2002) prepared the solid dispersions of 
griscofulvin using saccharides by a new method called roll mixing process. 
They investigated that the solubility of griseofulvin was higher in mixtures 
with higher molecular weight carriers such as corn starch and processed 
starch. The dissolution of  griseofulvin was markedly improved by the GF-
British gum role mixture. It was suggested that the saccharides with a high 
molecular weight are useful carriers of solid dispersions. 
Chen.Y et.al.,36 (2004) investigated a method of enhancing the 
bioavailability of ABT-963 using solid dispersion containing pluronic F-68. 
The dissolution rate and bioavailability of the poorly water soluble 
compound ABT-963 was substantially increased by solid dispersion. They 
investigated that the dosing of the dispersion to fasted dogs resulted in a 
significant oral bioavailability compared to the conventional capsule 
formulation. 
Gopal Rao et.al.,37 (2005) studied the preparation characterization 
of solid dispersions of naproxen using carriers such as PVP , PEG4000 
PEG2000, methyl cellulose and  β-cyclodextrin. A marked increase in 
dissolution rate was observed with all solid dispersions. Among the 
carriers used naproxen β-cyclodextrin gave the highest improvement in 
dissolution rate. 
Natalijazaje et.al.,38 (2005) studied the physical properties and 
dissolution behaviour of nifedipine with mannitol solid dispersions by hot 
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melt method. They investigated that the dissolution rate enhancement was 
attributed to improved wetting of nifedipine crystals due to mannitol 
particles, Attached on the surface, as inspected by means of scanning 
electron microscopy. 
Guy van den Mooter et.al.,39 (2006) reported an  increase in the 
dissolution rate of itraconazole by solid dispersions prepared with inutec 
SPI, a new polymeric surfactant by spray drying and hot-stage extrusion. 
The dissolution properties of the solid dispersions were significantly 
improved in comparison to pure itraconazole. 
Patel and Patel40., (2006) showed that there is a marked effect on 
enhancement of dissolution rate of valdecoxib when used as solid 
dispersion system. They used mannitol, polyethylene glycol4000, and 
polyvinyl pyrrolidne K-12 as carriers for the preparation of solid 
dispersions. The tablet formulation containing PVP K12 solid dispersions 
exhibits 100% drug release in 20min. 
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PURPOSE OF WORK 
 
      With the perspective of enhancing the bioavailability of drugs, much 
attention has been focussed on the problems of drug solubility. So poor 
solubility or poor wettability may lead to decrease in its bioavailability. The 
dissolution of the drug from its dosage form is an important parameter in the 
absorption which is also limiting step.  
The dissolution rate can be improved by increasing the surface area by 
reducing the particle size. There are several methods to reduce the particle 
size and they are (1) conventional trituration (2) ball milling (3) fluid energy 
micronization (4) controlled precipitation by change of solvents or temperature 
(5) application of ultrasonic waves and spray drying (6) Kneading method    
(7) Co-evaporation method. Although the reduction of size can be easily 
accomplished, the resultant fine particles may not produce the expected 
faster dissolution and absorption. This primarily results from possible 
aggregation and agglomeration of the fine particles due to their increased 
surface free energy and subsequent strong vanderwaal’s attraction between 
non-polar molecules. 
The present studies are aimed for overcoming these common 
problems by introducing solid dispersion technology using various carriers 
and thus improve its dissolution characteristics. This study deals with an 
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effective anti-inflammatory drug. Indomethacin which is poorly soluble in 
water where the dissolution rate is limited.  
 
The work was carried out according to the following steps: 
1. Literature survey on solid dispersions, methods and carriers for 
solid dispersion and for indomethacin. 
2. Preparation and Evaluation of Solid dispersions o indomethacin 
with  β-CD and HPβ-CD. 
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ANALYTICAL METHODS 
Indomethacin can be analysed by the following methods  
They are: 
Phosphorimetric determination of Indomethacin in pharmaceutical 
formulations45.  
 Spectroflourimetric, HPLC46 and colorimetric estimation in biological 
samples.  
Method used in this study 
Potassium dihydrogen phosphate, 0.2M solution 
          Accurately weight 27.318 gm of potassium dihydrogen phosphate is 
dissolved in 1000 ml of distilled water. 
Sodium hydroxide 0.2N solution 
           Accurately weigh 8 gm of sodium hydroxide and dissolved in 1000ml of 
distilled water. 
Preparation of pH 7 phosphate buffer  
          Place 50 ml of the 0.2M potassium dihydrogen phosphate in a standard 
volumetric flask. Add 29.1 ml of 0.2M sodium hydroxide solution to the flask 
and make up the  volume with distilled water. 
Preparation of pH7.2 phosphate buffer 
         Place 50 ml of potassium dihydrogen phosphate in a 200 ml standard 
volumetric flask. Add 4.7 ml of sodium hydroxide solution to this flask and 
make up the volume with distilled water. 
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Procedure for standard graph preparation  
              Accurately weigh 100 mg of indomethacin and transfer to a 100 ml 
volumetric flask. Add minimum quantity of methanol to get a clear solution. 
Then add phosphate buffer pH7.0 to make up the volume to 1000 µg/ml. This 
gives stock solution. 
             From this solution pipette out 1 ml and make up the volume to 10 ml 
with phosphate buffer pH7.0. This solution contains 100 µg/ml. 
   From above solution pipette out 0.5 ml, 1 ml, 1.5 ml, 2 ml, 2.5 ml, 3 ml 
into five separate test tubes and then make up the volume to 10 ml to give    
5, 10, 15, 20, 25 and 30 µg/ml concentrated solution. A blank was also 
prepared with out drug. The absorbance was measured at 320 nm. 
 The results are shown in the below table no 2  and figure no.2 follows: 
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Table no : 2 ABSORBANCE OF INDOMETHACIN              
Sl.No Concentration in µg/ml Absorbance at 320 nm 
1 5 0.26 
2 10 0.521 
3 15 0.779 
4 20 1.049 
5 25 1.306 
6 30 1.578 
 
Figure no : 2 STANDARD GRAPH OF INDOMETHACIN 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 5 10 15 20 25 30 35
Concentration in µg/ml
A
bs
or
an
ce
 a
t 3
20
 n
m
 
 
Chapter 7                                                                     Preparation And Evaluation  
 48
PREPARATION AND EVALUATION OF INDOMETHACIN  
SOLID DISPERSIONS  
 
Materials and equipment used 
Indomethacin                               -         Max India Limited, Mysore. 
β-cyclodextrin                             -         Burgoyner Burbidges and Co.. 
                                                               Mumbai. 
Hydroxypropyl-β-cyclodextrin   -         Burgoyner Burbidges and Co.. 
                                                               Mumbai 
Methanol                                    -          Fischer Inorganics, Chennai 
.Chloroform                                 -          Fischer Inorganics, Chennai                                    
Vacuum pump                            -          Gelman Sciences. 
Magnetic Stirrer                         -          SR No GEMS 1708 Demi Stirrer  
                                                              Equipment, Mumbai. 
Dissolution Apparatus               -       Electro Lab TDT-08L 
UV/Vis. Spectrophotometer           -         JASCO V-530  
Analytical Balance                    -          Dhona 200D. 
SOLID DISPERSIONS  OF INDOMETHACIN 
Solid dispersions technology can be used to improve the in-vitro 
and in-vivo dissolution properties of poorly water soluble drugs. 
Indomethacin is practically insoluble in water; the dissolution rate from 
solid dispersion was effected by carrier concentration. β-cyclodextrin and 
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hydroxypropyl-β-cyclodextrins at drug:carrier ratios of 1:1, 1:3, 1:9 were 
prepared using kneading and co-evaporation methods. 
PROCEDURE FOR PREPARATION OF SOLID DISPERSIONS OF 
INDOMETHACIN BY CO-EVAPORATION METHOD 
         Methanol was used as a solvent. The aqueous solution of 
cyclodextrin was added to the solution of indomethacin methanol. The 
resulting mixture was stirred for one hour and evaporated at a temperature 
of 550C in the hot air oven until dry. The dried mass was pulverised and 
sieved through mesh no 100. 
PROCEDURE FOR PREPARATION OF SOLID DISPERSION OF 
INDOMETHACIN BY KNEADING METHOD 
         The solvent blend of methanol and water is used here. 
Indomethacin and cyclodextrin were triturated in mortar with small volume 
of solvent blend of water-methanol. The thick slurry was kneaded for       
45 min and then dried at 550C in the hot air oven till it gets dried. The dried 
mass was pulverised and sieved through 100 mesh. 
 
Table no : 3 DRUG CARRIER RATIOS AND RESPECTIVE AMOUNTS 
TAKEN FOR SOLID DISPERSION 
Drug carrier ratio Drug (mg) Carrier (mg) 
1:1 1000 1000 
1:3 500 1500 
1:9 200 1800 
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CHARACTERISATION OF INDOMETHACIN SOLID DISPERSION 
• Thin layer chromatography  
• IR spectral analysis  
• X-ray diffraction studies 
• Differential scanning calorimetry 
EVALUATION OF INDOMETHACIN SOLID DISPERSION  
• Drug content uniformity 
• In-vitro dissolution studies 
THIN LAYER CHROMATOGRAPHY  
A thin layer chromatographic method was carried out to study the 
interaction between the drug and the carrier and also to confirm the 
chemical stability of the solid dispersions prepared. For this, pure 
indomethacin and the solid dispersions prepared with various carriers by 
solvent evaporation method and kneading method at 50:50 ratios were 
subjected to chromatographic studies. Which are shown in table no.4. 
The TLC system used for the study is given below   
 Precoated TLC plates :  manufactured by SD fine Chemicals ltd,  Mumbai. 
Absorbent layer   :         Silica gel  GF 254 
Layer thickness    :         250 µm 
Size       :         10 Х 20 cm  
Separation technique  :         Ascending 
Chamber saturation  :         The chamber was lined on three sides  
with filter paper and saturated for  
45 min. 
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Mobile phase        :   Mixture of 70 volumes of ether and 30  
volumes of light petroleum 
Preparation of sample : Suitable quantity of the sample was  
dissolved in methanol and  spotted.          
Amount applied   : 10 µL 
Detection   :          Iodine chamber 
. 
Table no : 4 Rf VALUES OF DRUG AND COMBINATION WITH 
POLYMERS 
Sample Rf value Number of spots 
Pure drug 0.4886 Single 
INM:β-CD (Co-evaporation) 0.4892 Single 
INM : β-CD (Kneading) 0.4962 Single 
INM:HPβ-CD (Co-evaporation) 0.4914 Single 
INM:HP β-CD (Kneading) 0.4862 Single 
INM : Mixture of polymers(Kneading) 0.4722 Single 
INM : β-CD (Physical mixture) 0.4882 Single 
INM : HP β-CD (Physical mixture) 0.4916 Single 
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Figure no.3. TLC  OF INDOMETHACIN AND SOLID DISPERSIONS 
WITH β-CD AND HPβ-CD AND COMBINATION OF β-CD AND HPβ-CD. 
     
 
    P= Pure drug of INM 
    SD= Solid Dispersion of  
    INM : HPβ-CD (1:1) 
                                                                                                          
                                                                    
 
 
 
 
 
 
P= Pure drug of INM                                                  P = Pure drug of  INM 
SD= Solid Dispersion of                                           SD = Solid Dispersion 
of INM : β-CD (1:1)     INM : β-CD & HPβ-CD(1:1) 
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FT-IR SPECTRAL ANALYSIS 
Using Fourier Transform Infra Red (FTIR) spectrometer 
compatibility studies of both drug and solid dispersions were carried out. 
The IR spectra obtained is given in figure 4 to 8. It was observed that the 
IR spectra for pure indomethacin were matching with that of indomethacin 
reference standard spectrum.  
The spectra obtained from solid dispersions matched with the 
original spectra. Hence there was no appearance or disappearance of any 
characteristic peaks, which confirmed the absence of chemical interaction 
between the drug and the carriers used.        . 
POWDER X-RAY DIFFRACTOMETRY  
The powder X-Ray Diffraction patterns were recorded using a 
Siemens Kristallofex D-5000 diffractometer ( Siemen, Munich, Germany 
)with Cu as  anode material and crystal graphite monochromator operated 
at a voltage of 40 Kv and a current of 30mA. The samples were analysed 
in the 2θ angle range of 2º to 65º and the process parameters. Which are 
shown in figure no.9 to 12.  
DIFFERENTIAL SCANNING CALORIMETRY  
The DSC measurements were performed using mettler- Toledo 
DSC module controlled by STARe software (Mettler-Toledo GmBH 
Switzerland). All accurately weighed samples (1 mg of Indomethacin or its 
equivalents) were placed in sealed aluminium pans, before heating under 
nitrogen flow (20 ml/min) at a scanning rate of 100Cmin-1, over the 
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temperature range of 300C – 2200C. An empty aluminium pan was used as 
reference. The figures are shown 13-17. 
DRUG CONTENT UNIFORMITY  
The Indomethacin solid dispersion which was prepared was tested 
for the drug content uniformity. From each batch of solid dispersion 
prepared in different ratios, 100 mg of Indomethacin solid dispersions were 
taken and analyzed for drug content uniformity. Which are shown in    
table no.5. 
Estimation of Indomethacin In Solid Dispersion By UV Spectroscopy 
Accurately weighed amount of SD was dissolved in 100 ml of o.1M 
pH 7.2 buffer phosphate buffer in a 100 ml volumetric flask which was 
previously cleaned and dried. The  is solution after suitable dilution was 
measured for absorption at 320 nm in a JASCO V-530 UV-Visible 
spectrophotometer. The results are shown below. 
Table no : 5 DRUG CONTENT UNIFORMITY 
Solid dispersions Drug: carrier 
Amount 
of SD 
Taken 
Expected 
amount of 
indomethacin 
in SD (mg) 
%of indomethacin 
estimated by UV 
spectrophotometer 
Indomethacin β 
CD (co-
evaporation) 
1:1 
1:3 
1:9 
200.00 
400.00 
1000.00 
100 
100 
100 
96.2 
98.2 
99.6 
Indomethacin β 
CD (KM) 
1:1 
1:3 
1:9 
200.00 
400.00 
1000.00 
100 
100 
100 
93.2 
94.6 
98.4 
Indomethacin HP 
β CD (co-
evaporation) 
1:1 
1:3 
1:9 
200.00 
400.00 
1000.00 
100 
100 
100 
97.4 
98.6 
99.8 
Indomethacin HP 
β CD (KM) 
1:1 
1:3 
1:9 
200.00 
400.00 
1000.00 
100 
100 
100 
97.4 
98.4 
99.8 
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Figure no.4. FT - IR SPECTRA OF INDOMETHACIN 
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Figure no.5. FT - IR SPECTRA OF INDOMETHACIN : β-CD IN THE RATIO OF 1:1 (CO-EVAPORATION METHOD ) 
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Figure no.6. FT – IR SPECTRA OF INDOMETHACIN : β-CD IN THE RATIO OF 1:1 (KNEADING METHOD ) 
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Figure no.7  FT - IR SPECTRA OF INDOMETHACIN : HPβ-CD IN THE RATIO OF 1:1 (CO-EVAPORATION METHOD ) 
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Figure no.8.  FT -  IR SPECTRA OF INDOMETHACIN : HPβ-CD IN THE RATIO OF 1:1 (KNEADING METHOD ) 
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Figure no.9. X-RAY DIFFRACTION STUDIES OF INDOMETHACIN SOLID DISPERSION WITH HPβ-CD 1: 1 
(KNEADING METHOD  ) 
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Figure no.10 X-RAY DIFFRACTION STUDIES OF INDOMETHACIN SOLID DISPERSION WITH HPβ-CD AND β-CD 1:1  
(KNEADING METHOD) 
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Figure no.11. X-RAY DIFFRACTION STUDIES OF INDOMETHACIN SOLID DISPERSION WITH β-CD 1:1 
(KNEADING METHOD) 
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Figure no.12. X-RAY DIFFRACTION STUDIES OF INDOMETHACIN SOLID DISPERSION WITH β-CD 1:1 
(CO-EVAPORATION METHOD) 
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Figure No.13. DSC STUDIES OF INDOMETHACIN SOLID DISPERSION WITH HPβ-CD 1:1 
(CO-EVAPORATION METHOD) 
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Figure no.14. DSC STUDIES OF INDOMETHACIN SOLID DISPERSION WITH HPβ-CD 1:1 
(KNEADING METHOD) 
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Figure no.15. DSC STUDIES OF INDOMETHACIN SOLID DISPERSION WITH β-CD AND HPβ-CD 1:1 
(KNEADING METHOD) 
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Figure no.16. DSC STUDIES OF INDOMETHACIN SOLID DISPERSION WITH β-CD 1:1 
(KNEADING METHOD) 
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Figure no.17. DSC STUDIES OF INDOMETHACIN SOLID DISPERSION WITH β-CD 1:1 
(CO-EVAPORATION METHOD) 
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IN-VITRO DISSOLUTION STUDIES OF DIFFERENT SOLID 
DISPERSIONS OF INDOMETHACIN  
The dissolution studies are the most important part of the evaluation 
of a solid dispersion, where the dissolution of pure drug and solid 
dispersion is carried out. Dissolution rate studies of various solid 
dispersions were carried out in 0.1M pH 7.2 phosphate buffer using XXII 
dissolution rate apparatus (Electrolab). Which are shown in tables 6-14 
and figures 18-24. 
DISSOLUTION METHOD 
900 ml of 0.1M pH 7.2 phosphate buffer was used as dissolution 
medium. Solid dispersions equivalent to 100 mg of Indomethacin was 
taken in hard gelatin capsule; a stainless steel wire was wound around the 
capsule as a sink. The paddle type stirrer was adjusted to 100 rpm. The 
temperature was maintained at 37.40C, 5 ml of aliquot dissolution media 
was withdrawn at different time intervals and volume withdrawn was 
replaced with fresh quantity of dissolution media. The samples were 
analyzed for Indomethacin after suitable dilution by measuring absorbance 
at 320nm using JASCO V-530UV-Visible spectrophotometer. 0.1M pH 7.2 
phosphate buffer was used as a blank. The percentage of Indomethacin 
dissolved at various time intervals was calculated and plotted against time. 
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Table no : 6 DISSOLUTION PROFILE OF INDOMETHACIN IN PURE 
FORM,PHYSICAL MIXTURE AND  FROM SOLID DISPERSIONS 
PREPARED BY CO-EVAPORATION METHOD CONTAINING β-
CYCLODEXTRIN AT DIFFERENT DRUG:CARRIER RATIOS  
 
Percentage of indomethacin dissolved from Time 
in min Pure drug PM 1:1 1:3 1:9 
5 2.25 1.125 2.65 10.87 9.15 
10 8.12. 2.27 5.75 19.85 18.175 
15 15.75 7.05 10.82 33.75 25.17 
30 24.12 12.375 27.85 65.75 41.55 
45 30.42 39.5 59.17 70.85 74.85 
60 39.17 61.75 72.75 78.12 83.12 
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Table no : 7  DISSOLUTION PROFILE OF INDOMETHACIN IN PURE 
FORM, PHYSICAL MIXTURE AND FROM SOLID DISPERSIONS 
PREPARED BY KNEADING TECHNIQUE   CONTAINING       
β-CYCLODEXTRIN  AT DIFFERENT DRUG:CARRIER RATIOS 
 
 
 
 
 
 
 
Percentage of indomethacin dissolved from Time 
in min 
Pure drug PM 1:1 1:3 1:9 
5 2.25 1.125 2.75 2.75 5.25 
10 8.12. 2.27 4.25 4.87 9.15 
15 15.75 7.05 10.12 14.5 20.02 
30 24.12 12.375 24.62 29.25 39.12 
45 30.42 39.5 48.5 56.25 65.25 
60 39.17 61.75 76.5 78.92 89.12 
 
Chapter 7                                                                     Preparation And Evaluation  
 73
 
 
 
 
 
 
 
 
 
 
Chapter 7                                                                     Preparation And Evaluation  
 74
Table no : 8  DISSOLUTION PROFILE OF INDOMETHACIN IN PURE 
FORM PHYSICAL MIXTURE AND FROM SOLID DISPERSIONS 
PREPARED BY CO-EVAPORATION METHOD CONTAINING HPβ-CD 
AT DIFFERENT DRUG:CARRIER RATIOS 
 
 
 
 
 
 
 
Percentage of indomethacin dissolved from Time 
in min 
Pure drug PM 1:1 1:3 1:9 
5 2.25 10.125 2.25 2.25 2.15 
10 8.12. 14.72 5.15 9.25 4.37 
15 15.75 21.23 15.75 13.15 21.15 
30 24.12 41.035 25.75 25.42 37.15 
45 30.42 51.025 54.15 45.75 61.37 
60 39.17 78.08 67.87 72.62 81.32 
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Table no.9. DISSOLUTION PROFILE OF INDOMETHACIN IN PURE 
FORM  AND FROM SOLID DISPERSIONS PREPARED BY KNEADING 
TECHNIQUE CONTAINING HPβ-CD AT DIFFERENT DRUG:CARRIER 
RATIOS 
 
 
 
 
 
 
 
Percentage of indomethacin dissolved from Time 
in min 
Pure drug PM 1:1 1:3 1:9 
5 2.25 10.125 10.125 6.75 4.25 
10 8.12. 14.72 14.72 17.12 13.5 
15 15.75 21.23 21.23 50.47 33.15 
30 24.12 41.035 41.035 59.125 42.75 
45 30.42 51.025 51.025 73.25 78.75 
60 39.17 78.08 78.08 85.5 91.75 
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Table no : 10  DISSOLUTION PROFILE OF INDOMETHACIN IN PURE 
FORM AND FROM SOLID DISPERSIONS PREPARED WITH VARIOUS 
CARRIERS AT DRUG:CARRIER RATIO 1:1 
 
 
Dissolution of indomethacin from various solid dispersions at  
drug : carrier ratio 1:1 
Time in 
min 
Pure 
drug 
β-CD 
CO 
β-CD 
KM 
HPβ-CD 
CO 
HPβ-CD 
KM 
Combination 
of β-CD & 
HPβ-CD 
5 2.25 2.65 2.75 2.25 10.125 2.25 
10 8.12. 5.75 4.25 5.15 14.72 7.75 
15 15.75 10.82 10.12 15.75 21.23 29.27 
30 24.12 27.85 24.62 25.75 41.035 35.75 
45 30.42 59.17 48.5 54.15 51.025 69.27 
60 39.17 72.75 76.5 67.87 78.08 76.75 
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Table no.11 DISSOLUTION PROFILE OF INDOMETHACININ PURE FORM 
AND  FROM SOLID DISPERSIONS PREPARED WITH VARIOUS 
CARRIERS AT  DRUG:CARRIER RATIO 1:3 
  
Dissolution of indomethacin from various solid dispersions at  
drug : carrier ratio 1:3 Time in 
min 
Pure 
drug 
β-CD 
CO 
β-CD 
KM 
HPβ-CD 
CO 
HPβ-CD 
KM 
Combination of 
β-CD & 
HPβ-CD 
5 2.25 10.87 2.75 2.25 6.75 2.65 
10 8.12. 19.85 4.87 9.25 17.12 8.75 
15 15.75 33.75 14.5 13.15 50.47 27.27 
30 24.12 65.75 29.25 25.42 59.125 37.17 
45 30.42 70.85 56.25 45.75 73.25 59.17 
60 39.17 78.12 78.92 72.62 85.5 77.25 
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Table no : 12  DISSOLUTION PROFILE OF INDOMETHACIN IN PURE 
FORM AND  FROM SOLID DISPERSIONS PREPARED WITH VARIOUS 
CARRIERS  AT DRUG: CARRIER RATIO 1:9 
 
Dissolution of indomethacin from various solid dispersions at 
drug : carrier ratio 1:9 
Time in 
min Pure 
drug 
β-CD 
CO 
β-CD 
KM 
HPβ-CD 
CO 
HPβ-CD 
KM 
Combination of 
β-CD & 
HPβ-CD 
5 2.25 9.15 5.25 2.15 4.25 4.75 
10 8.12. 18.175 9.15 4.37 13.5 10.475 
15 15.75 25.17 20.02 21.15 33.15 33.75 
30 24.12 41.55 39.12 37.15 42.75 42.175 
45 30.42 74.85 65.25 61.37 78.75 54.75 
60 39.17 83.12 89.12 81.32 91.75 80.175 
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Table no : 13  PERCENTAGE RELEASE OF INDOMETHACIN FROM VARIOUS SOLID DISPERSIONS 
 
percentage  of Indomethacin released from 
With HPβ-CD With β-CD 
PM 
Co-evaporation 
method 
Kneading method PM 
Co-evaporation  
method 
Kneading method 
Combination of β-CD 
& HPβ-CD(kneading) 
 
 
Time 
In 
Min 
 
Pure 
drug 
1:1 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 
5 2.25 10.125 2.25 2.25 2.15 10.125 6.75 4.25 1.125 2.65 10.87 9.15 2.75 2.75 5.25 2.25 2.65 4.75 
10 8.12. 14.72 5.15 9.25 4.37 14.72 17.12 13.5 2.27 5.75 19.85 18.175 4.25 4.87 9.15 7.75 8.75 10.475 
15 15.75 21.23 15.75 13.15 21.15 21.23 50.47 33.15 7.05 10.82 33.75 25.17 10.12 14.5 20.02 29.27 27.27 33.75 
30 24.12 41.035 25.75 25.42 37.15 41.035 59.125 42.75 12.375 27.85 65.75 41.55 24.62 29.25 39.12 35.75 37.17 42.175 
45 30.42 51.025 54.15 45.75 61.37 51.025 73.25 78.75 39.5 59.17 70.85 74.85 48.5 56.25 65.25 69.27 59.17 54.75 
60 39.17 78.08 67.87 72.62 81.32 78.08 85.5 91.75 61.75 72.75 78.12 83.12 76.5 78.92 89.12 76.75 77.25 80.175 
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Table no .14  FIRST ORDER RATE CONSTANTS FOR INDOMETHACIN 
FROM VAROIUS SOLID DISPERSIONS 
 
           SOLID DISPERSION                           K(MIN-1) 
INDOMETHACIN 0.036 
INDOMETHACIN:HPΒ-CD  
PHYSICAL MIXTURE 0.00222 
1:1         0.0179 
1:3 0.0181 
1:9 0.0238 
INDOMETHACIN:Β-CD(CO)  
PHYSICAL MIXTURE 0.009198 
1:1 0.0201 
1:3 0.020 
1:9 0.0349 
INDOMETHACIN: Β-CD(KM)  
PHYSICAL MIXTURE 0.009543 
1:1 0.0178 
1:3 0.0154 
1:9 0.022 
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RESULTS AND DISCUSSION 
 
    Solid dispersions of Indomethacin was prepared with polymer β-
Cyclodextrin and HPβ-CD using kneading and co-evaporation methods, were 
found to be free flowing powder. Characterization of solid dispersion was 
done by TLC, IR spectral analysis, X-Ray diffraction and differential scanning 
calorimetry. 
Thin layer chromatography  
Solid dispersions of Indomethacin gave a single spot corresponding to 
Indomethacin pure drug. Similar Rf values were obtained for pure drug and 
solid dispersions of Indomethacin. TLC studies thus indicated no interactions 
between drug and the carriers in the solid dispersions prepared. 
FT - IR spectral studies 
The solid dispersions of Indomethacin and pure drug were studied for 
IR analysis. Identical IR spectrums were obtained for pure drug and solid 
dispersions. This confirmed the absence of any chemical interaction between 
drug and the carrier  
X-Ray diffraction  
Patterns of pure drug showed intensive peaks indicating the crystalline 
nature of Indomethacin, which is reduced in solid dispersions where the 
peaks indicate the amorphous nature of Indomethacin, which might be the 
reason for improved dissolution characteristics of solid dispersions. 
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Differential scanning calorimetry 
DSC thermogram of Indomethacin from all solid dispersions shows that 
there was no interaction between the drug and the carrier used and 
amorphous character of the drug in the solid dispersions. 
Dissolution studies  
Dissolution rate of Indomethacin from all solid dispersions was found to 
be increased when compared to the physical mixture and pure Indomethacin. 
The dissolution of solid dispersions followed first order kinetics. The solid 
dispersions with both the cyclodextrins, at the ratio of 1:9 (drug: carrier) 
exhibited the highest rate of dissolution and moreover the solid dispersion 
prepared by complexation exhibited the highest dissolution rate and efficiency 
than those prepared by kneading method. 
The drug release from the solid dispersion after 30 minutes of 
dissolution for the ratio of 1:9 was more than 50% where as for the physical 
mixture and pure drug it was around 30%.  
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SUMMARY AND CONCLUSION 
 
    Indomethacin solid dispersions were prepared using carriers such as  
β-CD and HPβ-CD. In this present study the solid dispersions were prepared 
by Co-evaporation for both the polymers and kneading method for β-CD and 
HPβ-CD.   
 
   The solid dispersions prepared were found to be free flowing powders. 
In TLC studies single spots appeared for pure drug and solid dispersions 
shows that there was no interaction between the drug and the carrier used. 
 
The IR spectra obtained for the solid dispersions were matching with 
reference standards. This indicates that the drug was pure and the spectra 
obtained from solid dispersions were matching with the original spectra. No 
characteristic peaks were disappeared or newly appeared which confirmed 
the absence of any chemical interaction between the drug and the carrier. 
 
X-Ray diffraction studies revealed that the crystalline nature of 
Indomethacin in pure form was reduced in the solid dispersions and this might 
be the reason for increased dissolution rate. 
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DSC thermogram showed no interaction between drug and polymer. It 
also indicates the amorphous character of solid dispersion. 
 
Results of dissolution studies showed rapid and fast dissolution of 
Indomethacin from all solid dispersions when compared with physical mixture 
and pure drug. The dissolution from all dispersions showed first order 
kinetics. Among two Cyclodextrins, HPβ-CD gave the faster dissolution. 
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